Pfizer Inc (PFIZ34) — Cash Flow-to-Debt Ratio
Pfizer Inc (PFIZ34) has a Cash Flow-to-Debt Ratio of 0.02x as of March 2026, meaning its operating cash flow of R$2.62 Billion could theoretically repay 0% of its total liabilities (R$117.21 Billion) in one year. See Pfizer Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Pfizer Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Pfizer Inc across 12 annual periods. Also explore net asset momentum of Pfizer Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Pfizer Inc (2014–2025)
Year-by-year debt coverage analysis for Pfizer Inc. For market capitalisation and broader financial context, see how much is Pfizer Inc worth.
| Year | CF-to-Debt Ratio | Operating CF (BRL) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.10x | R$11.71 Billion | R$121.39 Billion | ▼ -5.5% |
| 2024 | 0.10x | R$12.74 Billion | R$124.90 Billion | ▲ +16.3% |
| 2023 | 0.09x | R$12.04 Billion | R$137.21 Billion | ▼ -69.6% |
| 2022 | 0.29x | R$29.27 Billion | R$101.55 Billion | ▼ -7.8% |
| 2021 | 0.31x | R$32.58 Billion | R$104.28 Billion | ▲ +97.4% |
| 2020 | 0.16x | R$14.40 Billion | R$90.99 Billion | ▲ +31.4% |
| 2019 | 0.12x | R$12.59 Billion | R$104.45 Billion | ▼ -26.9% |
| 2018 | 0.16x | R$15.83 Billion | R$96.02 Billion | ▼ -1.4% |
| 2017 | 0.17x | R$16.80 Billion | R$100.49 Billion | ▲ +15.7% |
| 2016 | 0.14x | R$16.19 Billion | R$112.07 Billion | ▲ +0.7% |
| 2015 | 0.14x | R$14.69 Billion | R$102.38 Billion | ▼ -19.4% |
| 2014 | 0.18x | R$17.08 Billion | R$95.94 Billion | — |